The abstract is read at the publisher; the summary is JClub's.
Transcatheter mitral valve replacement with the SAPIEN M3 system in ENCIRCLE’s high-risk symptomatic mitral regurgitation cohort sustained MR ≤1+ in 97.0% at 2 years.
- Why it matters: Longer-term durability and clinical risk tradeoffs are needed beyond 1-year results for patients with ≥3+ MR who are not suitable for surgery or edge-to-edge repair.
- What they did: In 299 treated patients (2-year data for 202/210 eligible; 96.2%), investigators assessed a nonhierarchical composite of all-cause mortality or heart failure hospitalization plus clinical, echocardiographic, functional, and health status endpoints.
- The result: At 2 years, the composite rate was 35.6% (25.1% all-cause mortality, 23.0% HFH), with disabling stroke 6.6%, valve thrombosis 7.1%, and hemolysis requiring intervention 7.6%, while NYHA I/II was 87.0% and Kansas City Cardiomyopathy Questionnaire increased by 17.2 points.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.